Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Quest Diagnostics Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.83 (market cap $1.69B), while Quest Diagnostics Inc trades at $209.36 (market cap $22.96B). The key difference: Quest Diagnostics Inc is far larger — about 13.6× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Quest Diagnostics Inc pays the higher dividend (1.66%). Which is the better fit depends on your goals.
| AMC | DGX | |
|---|---|---|
Market Cap | $1.69B | $22.96B |
Sector | Media | Health |
52-Week High | $3.54 | $216.02 |
52-Week Low | $0.95 | $166.42 |
Enterprise Value | $9.28B | $28.98B |
Dividend Yield | 0.11% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
Quest Diagnostics (DGX) trades at $207.44, down 0.29% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported $11.04B revenue in 2025 with a 9.08% net margin, supported by strong cash flow from operations of $1.89B. Recent news highlights expansion of oncology testing services, including New York State approval for Haystack MRD, enhancing its diagnostic portfolio.
DGX offers steady growth with a consensus price target of $226, implying 9% upside. Risks include rising debt levels and healthcare policy uncertainties, but analyst sentiment leans positive with 38% buy ratings. The stock's valuation at a P/E of 22.92 appears reasonable given its profitability and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
